Recent corporate and financial developments for Helus Pharma highlight its official corporate rebranding from Cybin Inc., alongside the transition of its trading presence on major exchanges under the ticker symbol HELP. News updates have focused heavily on executive leadership expansions—such as the appointment of new executive personnel—and ongoing clinical trial milestones for its proprietary novel serotonergic agonists targeting major depressive disorder and generalized anxiety disorder. Financial analysts regularly track its quarterly cash burn rates, operational runway, and regulatory updates from health authorities regarding its breakthrough therapy designations. Detailed press releases and official investor relations summaries provide precise updates on these ongoing corporate milestones.